Alaunos Therapeutics, Inc.

NasdaqCM:TCRT Stok Raporu

Piyasa değeri: US$3.7m

Alaunos Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Alaunos Therapeutics CEO'su Dale Hogue, Jan2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.25% doğrudan sahiptir ve bu hisselerin değeri $ 9.28K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 3.9 yıldır.

Anahtar bilgiler

Dale Hogue

İcra Kurulu Başkanı

US$11.1k

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresiless than a year
CEO sahipliği0.2%
Yönetim ortalama görev süresi3yrs
Yönetim Kurulu ortalama görev süresi3.9yrs

Son yönetim güncellemeleri

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Sep 15

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Aug 31

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Aug 15

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20
Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11
Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09
How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15
We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23
What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

CEO

Dale Hogue (54 yo)

less than a year

Görev süresi

US$11,090

Tazminat

Mr. Dale Curtis Hogue, Jr. is Director of Alaunos Therapeutics, Inc. from December 29, 2023 and also serves as Interim Chief Executive Officer from January 20, 2024. Mr. Hogue has worked in various roles...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Dale Hogue
Interim CEO & Directorless than a yearUS$11.09k0.25%
$ 9.3k
Melinda Lackey
Senior VP of Legal3yrsUS$701.74kVeri yok
Michael Wong
Vice President of Finance & Principal Accounting Officer3.2yrsVeri yokVeri yok

3.0yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim: TCRT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Dale Hogue
Interim CEO & Directorless than a yearUS$11.09k0.25%
$ 9.3k
Holger Weis
Independent Chairman of the Board3.9yrsUS$900.26k0.076%
$ 2.8k
Carl June
Chairman of Scientific Advisory Board4.4yrsVeri yokVeri yok
Jaime Vieser
Independent Director3.9yrsUS$103.26k0.97%
$ 35.9k
Matthew Porteus
Member of Scientific Advisory Board4.2yrsVeri yokVeri yok
Kole Roybal
Member of Scientific Advisory Board4.2yrsVeri yokVeri yok
Robert Hofmeister
Independent Director1.7yrsUS$84.01k0%
$ 0
Robert Postma
Independent Director3.8yrsUS$104.26k0.52%
$ 19.3k
Steven Feldman
Member of Scientific Advisory Boardno dataVeri yokVeri yok

3.9yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TCRT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).